Breaking Down Barriers to Pulmonary Therapies: Patient Education, Teach Back, and More Char Raley, RRT Brandon Johnson, PharmD, BCPS Pulmonary and Critical Care Symposium June 12 th, 2015 We have had no financial relationships over the past 12 months with any commercial sponsors with a vested interest in this presentation. Objectives Review recommended therapies for Chronic Obstructive Pulmonary Disease (COPD) Describe Teach-Back and how to utilize in respiratory therapy Identify barriers to pulmonary therapies and describe how to mitigate them 1
GOLD for COPD COLD COPD s Impact Fourth leading cause of death in the world Leading cause of morbidity and mortality in the world with significant economic and social burden Prevalence and burden are projected to increase Associated with many comorbidities World Health Report. Geneva: World Health Organization.; 2000. Lopez AD, et al. Eur Respir J 2006;27:397-412. Mathers CD, et al. PLoS Med. 2006;3:e442. Barnes PJ, et al. Eur Respir J 2009;33:1165-85. 2
Classification of Airway Limitation In patients with FEV1/FVC < 0.70 COPD Stage FEV 1 * Exacerbations/yr Hospitalizations/yr 3-yr mortality GOLD 1, Mild 80% Unknown Unknown Unknown GOLD 2, Moderate 50-79% 0.7-0.9 0.11-0.2 11% GOLD 3, Severe 30-50% 1.1-1.3 0.25-0.3 15% GOLD 4, Very Severe < 30% 1.2-2.0 0.4-0.54 24% *Post bronchodilator measurement Global Initiative for Chronic Obstructive Lung Disease. Accessed 2 Apr 2015. Maintenance: COPD Medications Long-acting beta 2 -agonists LABA Long-acting anticholinergic Inhaled Corticosteroids ICS Combo: LABA+ICS Methylxanthines (theophylline Systemic Steroids PDE4-inhibitor (roflumilast) As needed or Rescue : Short-acting beta 2 -agonists SABA Short-acting anticholinergic Combo: SABA + SA- Anticholinergic 3
+LA antichol. ± LABA+ICS +LA antichol. + LABA+ICS Adjunct Therapies: Theophylline PDE4-inhibitor Steroids SABA or LA-antichol. +LA antichol. Or LABA Non-pharmacologic Interventions COPD Assessment Essential Recommended Group A Groub B - D Smoking Cessation ±pharmacologic assistance Smoking Cessation ±pharmacologic assistance Pulmonary Rehab Physical Activity Yearly Influenza Vaccine Pneumococcal Vaccine Very Severe COPD therapy options: Oxygen therapy (>15 hours/day) Surgical Interventions 4
Teach Back Teach back is so important because it gives you an opportunity to see if your patient is understanding the education session. The main problem with communication is the assumption that it has occurred. -George Bernard Shaw 5
Health Literacy Strategies Are you speaking clearly and listening carefully? Is the information appropriate for the user? Is the information easy to use? Use a medically trained interpreter for language barriers Adapt for learning ability Check for understanding frequently 6
Use of Valved Holding Chambers Unless you ve got the reflexes of a NASCAR driver or compulsive video gamer, catching that fleeting premeasured dose in a slow, deep inhalation is almost impossible. ALLERGY & ASTHMA TODAY FAL L 2007 Spacer Technique (~3.5 years old) In-check Dial The DIAL can be adjusted to accurately simulate the resistance of popular inhaler devices which include MDI s and DPI s such as Turbuhaler, Flexhaler, Twisthaler, Aerolizer, Handihaler and Diskus among others. The In Check DIAL enables clinicians to train patients to the proper inspiratory technique considering force and flow rate to achieve optimal deposition of the medication being inhaled into the lungs. 2015 Alliance Tech Medical, Inc 7
RRT Barrier #1- Smoking Cessation The patient will not quit smoking until they are ready. Refer to your state quit line. Helpful hints. 8
RRT Barrier #2- Medication Cost Coupons/Programs Financial Advocates RRT Barrier #3 Med WRECK-onciliation Ask all the questions When, how many, show me! RRT Barrier #4- Meds prescribed at home are not consistent with GOLD Standards Make recommendations to the discharging docs. Fax the PCP after discharge if needed. 9
Pharmacist s role in care of inpatients Review patient cases and pharmacotherapy orders for inpatient and orders upon discharge Patient education based upon priority/complexity, discharge disposition, pharmacist and/or patient availability R x Barrier 1 Patient does not have pulmonary meds despite being diagnosed with COPD Possible med-reconciliation omission Medication cost issue 10
R x Barrier 2 Provider forgot to order Nebulizer-machine for new Neb-medications R x Barrier 3 Patients do not take pulmonary therapies as prescribed Maintenance meds are stopped when symptoms subside Complex medication regimen Multiple comorbidities Simplify when appropriate Leuppi JD, et al. JAMA. 2013;309(21):2223-2231 Medication cost R x Barrier 4 Patient has R x insurance related issues Preferred therapies vs less preferred therapies Medicare Part B (Nebs) vs. Part D (Inhalers) 24-hour Neb rule by Medicare 11
Success Stories Coordinating education and care from the time of admission with the entire medical team. Monthly multidisciplinary meetings Pharmacy Financial Advocates RT Education Care Transitions and Home Care Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of COPD. http://www.goldcopd.org/uploads/users/files/gold_report2014_feb07.pdf. Accessed 2 Apr 2015. World Health Report. Geneva: World Health Organization. Available from URL: http://www.who.int/whr/2000/en/ statistics.htm; 2000. Lopez AD, Shibuya K, Rao C, et al. Chronic obstructive pulmonary disease: current burden and future projections. Eur Respir J 2006;27:397-412. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006;3:e442. Barnes PJ, Celli BR. Systemic manifestations and comorbidities of COPD. Eur Respir J 2009;33:1165-85. Leuppi J, Schuetz P, Bingisser R, et al. Short-term vs conventional glucocorticoid therapy in acute exacerbations of chronic obstructive pulmonary disease. JAMA. 2013;309(21):2223-2231. Char Raley, RRT Questions? Avera McKennan Respiratory Therapy Coordinator of Pulmonary Education Charlene.Raley@Avera.org 605.322.8612 Brandon R. Johnson, Pharm D, BCPS Clinical Pharmacist Internal Medicine Brandon.Johnson@Avera.org 12